Pharmaceutical biocatalysis : important emzymes, novel targets, and therapies / edited by Peter Grunwald.

Call Number
660.634
Title
Pharmaceutical biocatalysis : important emzymes, novel targets, and therapies / edited by Peter Grunwald.
Physical Description
1 online resource : illustrations (black and white, and colour).
Series
Jenny Stanford series on biocatalysis ; volume 6
Summary
This volume of Pharmaceutical Biocatalysis starts with a discussion on the importance of biocatalytic synthesis approaches for a sustainable and environmentally friendly production of pharmaceuticals and active pharmaceutical ingredients. Among the enzymes discussed in detail with respect to their pharmaceutical relevance are cyclic nucleotide phosphodiesterases playing an important role in modulating signal transduction in various cell types; human DOPA decarboxylase, related to Parkinson's disease and aromatic amino acid decarboxylase deficiency; and phospholipase D enzymes as drug targets. Isocitrate dehydrogenase 1 and 2 mutations are novel therapeutic targets in acute myeloid leukemia. An additional chapter is devoted to the use of enzymes for prodrug activation in cancer therapy. The other topics include small-molecule inhibitors targeting receptor tyrosine kinases in cancer, -Lactams and related compounds as antibacterials, non-vitamin K oral anticoagulants for the treatment of thromboembolic diseases, and the molecular mechanisms for statin pleiotropy and its clinical relevance in cardiovascular diseases. The last chapter is a review of lysosomal storage disorders with an overview of approved drugs for treating these disorders by enzyme replacement therapy.
Added Author
Grunwald, Peter, 1941- editor.
Subject
Enzymes Industrial applications.
BIOCATALYSIS.
PHARMACEUTICAL CHEMISTRY.
MEDICAL / Pharmacy
SCIENCE / Biotechnology
SCIENCE / Chemistry / General
Multimedia
Total Ratings: 0
No records found to display.
 
 
 
03914cam a22006731i 4500
001
 
 
vtls001592516
003
 
 
VRT
005
 
 
20220808223100.0
006
 
 
m        d       
007
 
 
cr |||||||||||
008
 
 
220808s2021    si a    ob    000 0 eng d
020
$a 9781003045410 $q (electronic bk.)
020
$a 1003045413 $q (electronic bk.)
020
$a 9781000067392 $q (electronic bk. : Mobipocket)
020
$a 1000067394 $q (electronic bk. : Mobipocket)
020
$a 9781000067385 $q (electronic bk. : PDF)
020
$a 1000067386 $q (electronic bk. : PDF)
020
$a 9781000067378 $q electronic publication
020
$a 1000067378 $q electronic publication
020
$a 9781000067354 $q electronic book
020
$a 1000067351 $q electronic book
020
$a 9781000067361 $q Mobipocket electronic book
020
$a 100006736X $q Mobipocket electronic book
020
$a 9781003045397 $q electronic book
020
$a 1003045391 $q electronic book
020
$z 9789814877138 $q hardcover
024
7
$a 10.1201/9781003045397 $2 doi
035
$a (OCoLC)1202850119
035
$a (OCoLC-P)1202850119
035
$a (FlBoTFG)9781003045397
039
9
$a 202208082231 $b santha $y 202206301325 $z santha
040
$a OCoLC-P $b eng $e rda $e pn $c OCoLC-P
050
4
$a TP248.E5 $b P53 2021
072
7
$a MED $x 072000 $2 bisacsh
072
7
$a SCI $x 010000 $2 bisacsh
072
7
$a SCI $x 013000 $2 bisacsh
072
7
$a MQP $2 bicssc
082
0
4
$a 660.634 $2 23
245
0
0
$a Pharmaceutical biocatalysis : $b important emzymes, novel targets, and therapies / $c edited by Peter Grunwald.
264
1
$a Singapore : $b Jenny Stanford Publishing, $c [2021]
300
$a 1 online resource : $b illustrations (black and white, and colour).
336
$a text $2 rdacontent
336
$a still image $2 rdacontent
337
$a computer $2 rdamedia
338
$a online resource $2 rdacarrier
490
0
$a Jenny Stanford series on biocatalysis ; $v volume 6
520
$a This volume of Pharmaceutical Biocatalysis starts with a discussion on the importance of biocatalytic synthesis approaches for a sustainable and environmentally friendly production of pharmaceuticals and active pharmaceutical ingredients. Among the enzymes discussed in detail with respect to their pharmaceutical relevance are cyclic nucleotide phosphodiesterases playing an important role in modulating signal transduction in various cell types; human DOPA decarboxylase, related to Parkinson's disease and aromatic amino acid decarboxylase deficiency; and phospholipase D enzymes as drug targets. Isocitrate dehydrogenase 1 and 2 mutations are novel therapeutic targets in acute myeloid leukemia. An additional chapter is devoted to the use of enzymes for prodrug activation in cancer therapy. The other topics include small-molecule inhibitors targeting receptor tyrosine kinases in cancer, -Lactams and related compounds as antibacterials, non-vitamin K oral anticoagulants for the treatment of thromboembolic diseases, and the molecular mechanisms for statin pleiotropy and its clinical relevance in cardiovascular diseases. The last chapter is a review of lysosomal storage disorders with an overview of approved drugs for treating these disorders by enzyme replacement therapy.
588
$a OCLC-licensed vendor bibliographic record.
650
0
$a Enzymes $x Industrial applications.
650
0
$a BIOCATALYSIS.
650
0
$a PHARMACEUTICAL CHEMISTRY.
650
7
$a MEDICAL / Pharmacy $2 bisacsh
650
7
$a SCIENCE / Biotechnology $2 bisacsh
650
7
$a SCIENCE / Chemistry / General $2 bisacsh
700
1
$a Grunwald, Peter, $d 1941- $e editor.
856
4
0
$3 Taylor & Francis $u https://www.taylorfrancis.com/books/9781003045397
856
4
0
$3 Taylor & Francis $u https://www.taylorfrancis.com/books/9781003045410
856
4
2
$3 OCLC metadata license agreement $u http://www.oclc.org/content/dam/oclc/forms/terms/vbrl-201703.pdf
999
$a VIRTUA               
No Reviews to Display
Summary
This volume of Pharmaceutical Biocatalysis starts with a discussion on the importance of biocatalytic synthesis approaches for a sustainable and environmentally friendly production of pharmaceuticals and active pharmaceutical ingredients. Among the enzymes discussed in detail with respect to their pharmaceutical relevance are cyclic nucleotide phosphodiesterases playing an important role in modulating signal transduction in various cell types; human DOPA decarboxylase, related to Parkinson's disease and aromatic amino acid decarboxylase deficiency; and phospholipase D enzymes as drug targets. Isocitrate dehydrogenase 1 and 2 mutations are novel therapeutic targets in acute myeloid leukemia. An additional chapter is devoted to the use of enzymes for prodrug activation in cancer therapy. The other topics include small-molecule inhibitors targeting receptor tyrosine kinases in cancer, -Lactams and related compounds as antibacterials, non-vitamin K oral anticoagulants for the treatment of thromboembolic diseases, and the molecular mechanisms for statin pleiotropy and its clinical relevance in cardiovascular diseases. The last chapter is a review of lysosomal storage disorders with an overview of approved drugs for treating these disorders by enzyme replacement therapy.
Subject
Enzymes Industrial applications.
BIOCATALYSIS.
PHARMACEUTICAL CHEMISTRY.
MEDICAL / Pharmacy
SCIENCE / Biotechnology
SCIENCE / Chemistry / General
Multimedia